Previous studies have suggested that a type of medication called sulfonylureas, particularly Orinase (tolbutamide), may be unsafe for the heart. The FDA currently has a product-label warning for heart-related
SAN FRANCISCO, June 11, 2019 3 hrs ago
The PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care.
The primary endpoint was defined as the MACE
https://diatribe.org/time-range-tips-expert-defined-goals-plus-insights-almost-500000-freestyle-libre-users
The refined report has now been published online in ...
During a Monday afternoon session at the Scientific Sessions, Chloe Zera, MD, MPH, and Howard Berger, MD, debated the question of whether all pregnant women with gestational diabetes or preexisting diabetes should be induced by 38 weeks. Dr. Zera argued in favor of induction and Dr. Berger made the
Diabetes in Pregnancy
Florence 2019-05-29 - 06-01
Detta möte arrangeras vartannat år och hölls nu för femte gången och samlade ca 350 deltagare företrädesvis från Europa. Målgruppen är gynekologer/obstetriker, diabetologer och forskningsaktiva inom fältet. Vi lärde oss många nya förkortningar och en lista finns
Abbott said today that new data show its FreeStyle Libre continuous glucose monitoring (CGM) system significantly reduces hemoglobin A1c (HbA1c) levels in certain adults with type 2 diabetes.
Presented as a late-breaker at American Diabetes Association (ADA) annual conference in San Francisco, the
Guangwei Li,
Of 981 adults ages 60 or older with prediabetes who were followed for 12 years, 204 (22%) reverted to normoglycemia and 119 (13%) developed diabetes,
In a four-armed intervention study of adults with impaired glucose tolerance or newly diagnosed
PREVIEW is the largest randomized control trial (gold standard of clinical trials) to date on the prevention of type 2 diabetes in adults with prediabetes through diet and exercise. Participants
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C Gersteinet al
ABSTRACT
Summary Background
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for
Abstract Hertzel C Gersteinet al
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations.
We assessed the effect of the GLP-1
Pancreatic beta cells that do not produce sufficient insulin in people with type 2 diabetes (T2D) are not permanently damaged during the early stages of the disease and can be restored to normal function through the removal of excess fat in the cells, according to a study entitled “Remission of Type
SAN FRANCISCO — As automated insulindelivery is rapidly evolving, interchangeability between insulin pumps and sensors on the various platforms is emerging as a key component to moving the field forward.
Here at the American Diabetes Association (ADA) 2019 Scientific Sessions, many attendees who
Dr. Roy Beck on CGM Accuracy and Use: “The benefit is far exceeding the burden now.”
Jaeb Center’s Dr. Roy Beck provided a very positive overview of continuous glucose monitor (CGM) options in the US, covering the four available systems: Dexcom’s G6, Abbott’s FreeStyle Libre, Medtronic’s
SAN FRANCISCO — Young people who were diagnosed with type 2 diabetes in their early teens had an "alarming" high rate of diabetes-associated complications by the time they were in their mid-20s, in new research.
Moreover, among more
The question about real-world evidence is no longer whether data collected during routine clinical processes can be useful, but rather, how can it best be used?
Mikhail Kosiborod, MD
“In recent years we have several examples of large, international comparative effectiveness studies showing that on a
A pair of experts addressed about how intensive therapy should be to lower low-density lipoprotein (LDL) cholesterol during Friday’s session Is Very Aggressive Lowering of LDL Cholesterol Worthwhile?
Steven E. Nissen, MD, MACC
Arguing in favor of aggressive therapy, Steven E. Nissen, MD, MACC,
Recent clinical trials studying the safety and efficacy of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with diabetes have created opportunities for collaboration between cardiologists, diabetologists, primary health and
SAN FRANCISCO — Vitamin D3 supplementation in people at high risk of developing diabetes but who did not have vitamin Dinsufficiency does not reduce the chances of developing the disease compared with placebo, the new results of a randomized, placebo-controlled trial show.
The findings from the
Sida 9 av 59
